Clinical Trial Update: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing oral upadacitinib to subcutaneous adalimumab in adults with moderate to severe rheumatoid arthritis to assess changes in dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)
• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING